Data Openness Enquiry

Enquiry Status: Unresolved

Started: Sat May 29 17:07:27 2010
ID: 5a05df4b-75a2-4192-8f7a-7d259cde371f

Message:

To: sylvia@collaborativedr....

Subject: Data Openness Enquiry

Date: Sat May 29 17:07:27 2010

Status: Sent

Dear Cynthia,

Thank you for your announcement to me about the release of the GSK malaria data set [appended]. [It happens that I worked for Glaxo for many years].

We are very keen to know of fully Open Data sets (for example so we can list them in our CKAN, a rapidly growing resources of links to Open Data and their licences). I am writing to seek clarification of the 'openness' [1] of this data:

I wasn't able to find an explicit statement that the data was open such as a reference to an open knowledge or data license [2] so I'm writing to find out what the exact situation is. In particular we would like to know whether the material can be made available under an open license of some kind.

I also noticed that I have to register to use the data. In the OKF we find that registration is a serious barrier to access, especially for machines and we cannot regard data as fully Open in these cases.

I am sure that you will want to make your data completely Open and if you have any problems then members of OKF will certainly help. We regard these data sets as really vital and the lead in making them available is important in showing the way. Being able to show how licences are added is therefore really valuable.

Thank you very much for your time and I look forward to receiving your response.

Regards, Peter Murray-Rust

[1] http://www.opendefinition.org/1.0/
[2] http://www.opendefinition.org/licenses/

On Fri, May 28, 2010 at 7:16 PM, Sylvia Ernst wrote: 

Dear Peter,

May 19, 2010 was a historic day in drug discovery.  For the first time, a large pharmaceutical company released formerly proprietary screening data to the public.  GlaxoSmithKline made public nearly 13,500 compounds with known activity against the Malarial parasite P. falciparum. These compounds and their data are now available on CDD Public, as well as EMBL-EBI, and NLM's PubChem.

GSK has issued a press release about the data.  Please visit CDD's blog to read about this historical event and mine this powerful data-collection which you can register for here.  CDD was also featured in the Wall Street Journal on Wednesday.

While mining this dataset alone is very powerful, you can include all public access CDD data-collections into your data mining.  For that that please register here, or just enable them when you are logged in.

And let me know if you have any questions, I'd be happy to discuss with you.

Best Regards,

Sylvia

PS If you'd like to data-mine all CDD public data sets securely against your own proprietary data, please contact me for your options.

Sylvia Ernst, Ph.D.
Sr. Director, Community Growth
sylvia@collaborativedrug.com
www.collaborativedrug.com

This email was sent to xxx by sylvia@collaborativedrug.com.


Email Marketing by
Collaborative Drug Discovery | 1633 Bayshore Hwy, Suite 342 | Burlingame | CA | 94010

--
Sent by "Is It Open Data?" http://isitopendata.org/ A service which helps scholars (and others) to request information about the status and licensing of data and content.

Disclaimer: This message and any reply that you make will be published on the internet for anyone to access and copy. For more information see:

http://isitopendata.org/about/

Message:

To: Is It Open Enquiry Service <isitopen@okf....

Subject: Re: Data Openness Enquiry

Date: Tue Jun 1 20:34:34 2010

Status: Response

Dear Peter,

Thank you very much for your inquiry. CDD is proud to be one of the hosting platforms for the Malaria/GSK data using it's existing technology. CDD's technology provides free of charge public access to certain data collections, it is not an Open Access environment.

The data-collection itself is GSK's and - while we provide also the download as an SD file on CDD - we have not further rights to decide upon the data. You may want to connect directly with GSK about your interest in use and licensing questions. The best starting point might be the publishers/authors of the data-publication: http://www.nature.com/nature/journal/v465/n7296/abs/nature09107.html

Best! - Sylvia

Sylvia Ernst, Ph.D. Sr. Director, Community Growth cell: 510.846.0224 fax: 503.339.9908 sylvia@collaborativedrug.com www.collaborativedrug.com

On Sat, May 29, 2010 at 10:30 AM, Is It Open Enquiry Service isitopen@okfn.org wrote:

Dear Cynthia,

Thank you for your announcement to me about the release of the GSK malaria data set [appended]. [It happens that I worked for Glaxo for many years].

We are very keen to know of fully Open Data sets (for example so we can list them in our CKAN, a rapidly growing resources of links to Open Data and their licences). I am writing to seek clarification of the 'openness' [1] of this data:

I wasn't able to find an explicit statement that the data was open such as a reference to an open knowledge or data license [2] so I'm writing to find out what the exact situation is. In particular we would like to know whether the material can be made available under an open license of some kind.

I also noticed that I have to register to use the data. In the OKF we find that registration is a serious barrier to access, especially for machines and we cannot regard data as fully Open in these cases.

I am sure that you will want to make your data completely Open and if you have any problems then members of OKF will certainly help. We regard these data sets as really vital and the lead in making them available is important in showing the way. Being able to show how licences are added is therefore really valuable.

Thank you very much for your time and I look forward to receiving your response.

Regards, Peter Murray-Rust

[1] http://www.opendefinition.org/1.0/ [2] http://www.opendefinition.org/licenses/

On Fri, May 28, 2010 at 7:16 PM, Sylvia Ernst wrote:

Dear Peter,

May 19, 2010 was a historic day in drug discovery. For the first time, a large pharmaceutical company released formerly proprietary screening data to the public. GlaxoSmithKline made public nearly 13,500 compounds with known activity against the Malarial parasite P. falciparum. These compounds and their data are now available on CDD Public, as well as EMBL-EBI, and NLM's PubChem.

GSK has issued a press release about the data. Please visit CDD's blog to read about this historical event and mine this powerful data-collection which you can register for here. CDD was also featured in the Wall Street Journal on Wednesday.

While mining this dataset alone is very powerful, you can include all public access CDD data-collections into your data mining. For that that please register here, or just enable them when you are logged in.

And let me know if you have any questions, I'd be happy to discuss with you.

Best Regards,

Sylvia

PS If you'd like to data-mine all CDD public data sets securely against your own proprietary data, please contact me for your options.

Sylvia Ernst, Ph.D. Sr. Director, Community Growth sylvia@collaborativedrug.com www.collaborativedrug.com

This email was sent to xxx by sylvia@collaborativedrug.com.

Email Marketing by Collaborative Drug Discovery | 1633 Bayshore Hwy, Suite 342 | Burlingame | CA | 94010

-- Sent by "Is It Open Data?" http://isitopendata.org/ A service which helps scholars (and others) to request information about the status and licensing of data and content.

Disclaimer: This message and any reply that you make will be published on the internet for anyone to access and copy. For more information see:


http://isitopendata.org/about/